Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mind Medicine (DE:MMQ)
FRANKFURT:MMQ
Holding DE:MMQ?
Track your performance easily
MMQ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.22 - €12.03
Previous Close€8.79
Volume225.00
Average Volume (3M)462.00
Market Cap
€606.30M
Enterprise Value€387.14M
Total Cash (Recent Filing)$252.33M
Total Debt (Recent Filing)$14.19M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Aug 08, 2024EPS Estimate
-€0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding71,872,422
10 Day Avg. Volume419
30 Day Avg. Volume462
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)9.17
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.11
Forecast
1Y Price Target
€22.88Price Target Upside160.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Mind Medicine News
PremiumCompany Announcements
MindMed Advances GAD Treatment into Phase 3 Trials
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceLarge, rapid and durable benefit shown with MM120 in GAD, in a randomized, placebo-controlled phase 2b trial.
FDA DesignationFDA recently granted Breakthrough Therapy Designation to MM120, reducing regulatory risk.
Market PotentialGAD is a market with multi-$B blockbuster potential.
Bears Say
Clinical PracticesClinical conduct concerns related to psychotherapy, as well as concerns/risk related to the lack of standardization of active treatment sessions, have raised some concerns for other psychedelic products including MM120.
Regulatory IssuesFDA had also asked Lykos to collect more data on AEs and abuse potential during phase 3, which wasn't captured to FDA's satisfaction; MindMed can learn from this.
Research And DevelopmentICER’s initial draft evidence report pointed to multiple concerns and controversies related to Lykos’ MDMA-assisted therapy, including functional unblinding and bias.
---
MMQ FAQ
What was Mind Medicine’s price range in the past 12 months?
Mind Medicine lowest stock price was €2.22 and its highest was €12.03 in the past 12 months.
What is Mind Medicine’s market cap?
Currently, no data Available
When is Mind Medicine’s upcoming earnings report date?
Mind Medicine’s upcoming earnings report date is Aug 08, 2024 which is in 8 days.
How were Mind Medicine’s earnings last quarter?
Mind Medicine released its earnings results on May 08, 2024. The company reported -€1.049 earnings per share for the quarter, missing the consensus estimate of -€0.487 by -€0.562.
Is Mind Medicine overvalued?
According to Wall Street analysts Mind Medicine’s price is currently Undervalued.
Does Mind Medicine pay dividends?
Mind Medicine does not currently pay dividends.
What is Mind Medicine’s EPS estimate?
Mind Medicine’s EPS estimate is -€0.3.
How many shares outstanding does Mind Medicine have?
Mind Medicine has 72,075,070 shares outstanding.
What happened to Mind Medicine’s price movement after its last earnings report?
Mind Medicine reported an EPS of -€1.049 in its last earnings report, missing expectations of -€0.487. Following the earnings report the stock price went down -2.893%.
Which hedge fund is a major shareholder of Mind Medicine?
Currently, no hedge funds are holding shares in DE:MMQ
---
Mind Medicine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€22.88 (160.43% Upside)
€22.88 (160.43% Upside)
Blogger Sentiment
Bullish
DE:MMQ Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.71%
12-Months-Change
Fundamentals
Return on Equity
-76.79%
Trailing 12-Months
Asset Growth
77.16%
Trailing 12-Months
Company Description
Mind Medicine
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.
---
MMQ Earnings Call
Q1 2024
0:00 / 0:00
---
MMQ Stock 12 Month Forecast
Average Price Target
€22.88
▲(160.43% Upside)
Technical Analysis
Best Analysts Covering MMQ
1 Year
1 Year Success Rate
5/6 ratings generated profit
1 Year Average Return
+122.38%
reiterated a buy rating 4 months ago
Copying Elemer Piros's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +122.38% per trade.
---